Protai is a technology company.
Protai has raised $20.0M across 2 funding rounds.
Protai has raised $20.0M in total across 2 funding rounds.
Protai has raised $20.0M in total across 2 funding rounds.
Protai's investors include Company Capital, Grove Ventures, Pitango Venture Capital, Guy Ezekiel.
Protai is a biotechnology company that develops an AI-driven, proteomics-based platform for drug discovery, focusing on complex protein interactions to identify novel therapeutic targets primarily in oncology and immunology. Its proprietary AIMS™ platform integrates mass spectrometry-derived structural and functional proteomics data with advanced AI modeling to simulate disease biology at the protein level, enabling the discovery of innovative drugs and degraders that traditional methods often miss[1][2][5].
Founded by Eran Seger (CEO) and Kirill Pevzner (CTO), Protai emerged from the need to overcome limitations in current drug discovery, which frequently fails to address the complexity of protein networks driving diseases. By harmonizing vast proteomic datasets and leveraging AI tools like AlphaFold, Protai has built a vertically integrated platform that not only accelerates target identification but also improves prediction of patient responses to therapies. Early traction includes raising over $20 million in funding and advancing several biomarker-led therapeutic assets in discovery stages, alongside collaborations with pharmaceutical partners[2][3][6][7].
Protai rides the convergence of AI, proteomics, and structural biology, a trend transforming drug discovery by enabling molecular-level insights into disease mechanisms previously inaccessible. The timing is critical as AI models like AlphaFold revolutionize protein structure prediction, while mass spectrometry proteomics provides rich experimental data. This synergy allows Protai to address the high failure rates in clinical trials caused by poor target validation and patient response prediction. By focusing on protein-level disease drivers rather than solely genomic data, Protai influences the ecosystem toward more precise, mechanism-based therapeutics and biomarker development[1][4][6].
Looking ahead, Protai is poised to expand its pipeline and partnerships, particularly in immunology and inflammation, leveraging its platform to accelerate drug discovery and improve clinical outcomes. Trends shaping its journey include advances in AI-driven structural biology, integration of multi-omics data, and growing demand for precision medicine solutions. Protai’s influence is likely to grow as it demonstrates the value of proteomics-aware AI in uncovering novel drug targets and optimizing therapies, potentially setting new standards in biotech innovation and personalized treatment strategies[1][3][4].
In summary, Protai is transforming drug discovery by combining deep proteomic insights with AI, addressing complex disease biology at the protein level, and paving the way for breakthrough therapies in oncology and immunology.
Protai has raised $20.0M across 2 funding rounds. Most recently, it raised $12.0M Seed in March 2023.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Mar 1, 2023 | $12.0M Seed | Company Capital, Grove Ventures, Pitango Venture Capital, Guy Ezekiel | |
| Jan 1, 2022 | $8.0M Seed | Company Capital, Grove Ventures, Pitango Venture Capital, Guy Ezekiel |